Collectively, our results indicate that TRIM38 is a novel regulator of NASH and that its function is mainly to promote the degradation of TAB2 and inhibit the TAK1-MAPK signaling pathway. This evidence concerns the gene MAP3K7 and metabolic dysfunction-associated steatohepatitis.